Early neurological deterioration (END) is not uncommon in patients with branch atheromatous disease.

We evaluated whether tissue plasminogen activator (tPA) can prevent END and improve patient outcome.

Intravenous tPA may not prevent END and guarantee good functional outcome in branch atheromatous disease.

More effective strategies should be evaluated for management of branch atheromatous disease.